Call for Abstracts: DIA EuroMeeting 2017

DIA29 - 31 March 2017, Glasgow, UK.
The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and access process to debate and find solutions to some of the most pertinent challenges faced in an ever-evolving healthcare system - including the need to drive innovation.

DIA invites you to submit presentation, session and tutorial abstracts for the 29th Annual EuroMeeting in Glasgow, UK. You may submit more than one abstract. Abstracts should fall under one of the themes detailed bellow.

Session Abstract
A session abstract is a 90-minute session concept delivered lecture-style from the podium. The abstract author is considered the session chair and will coordinate efforts in recruiting speakers and managing the session (including the facilitation of question and answers from the audience). PowerPoint presentations are required. We encourage innovative ideas for session formats that will enhance interaction between stakeholders.

Presentation Abstract
A presentation abstract is for a 20-minute presentation in a specific topic area; the abstract author is considered the speaker. A PowerPoint presentation is required. If selected, the abstract will consist of a single presentation which will fit within a session.

Tutorial Abstract
A tutorial is a 'hands-on', interactive learning experience. A tutorial consists of 3 hours of instruction with a 30-minute break. The abstract author is considered the instructor. One co-instructor may be recruited but cannot be from the same company/organisation as the author.

Hot-Topic / Stand-Alone Sessions
Each year, there are a number of sessions which do not fit directly under the programme themes. If your abstract clearly does not fit with any of the themes / topics outlined, you may submit it for consideration as a hot-topic / stand-alone presentation or session.

How to maximise the probability of your abstract being accepted
Abstracts will be selected by the EuroMeeting Programme Committee. The theme leaders have indicated the strategic topics they would like to address.

  • Focus your abstracts on the proposed topics in this flyer. If your abstract clearly does not fit, submit it as a hot topic / stand-alone presentation or session
  • Your abstract should be as clear and as detailed as possible to enable the theme leaders to make a judgement on its suitability for the programme
  • Abstracts must be non-promotional and non-commercial in order to be considered

If you have any questions about abstract submission, please email the EuroMeeting team: This email address is being protected from spambots. You need JavaScript enabled to view it.

The deadline for submitting abstracts is Monday, 27 June 2016.

For further information, please visit:
http://www.diaglobal.org/en/conference-listing/meetings/2017/03/29th-annual-euromeeting

About DIA
For over 50 years, DIA has served as a global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally through the advancement of lifesaving medicines and technologies. As the premier professional community for the health care product development ecosystem, DIA (the Drug Information Association) provides global players a neutral and transparent forum for the exchange of ideas and collaboration. By offering access to tools, resources, and networking opportunities, DIA provides its members and international participants objective opportunities for extending debate and discussion to advance scientific and medical innovation.

DIA is an independent, global nonprofit organization based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, the Middle East, and Africa (Basel, Switzerland); and Asia (Beijing, China; Mumbai, India; and, Tokyo, Japan).

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Novartis presents first-of-its-kind algorithm-base…

Novartis today announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool a...